VanEck Pharmaceutical ETF (PPH)

Delayed Data
As of Dec 02
 +0.20 / +0.26%
Today’s Change
Today|||52-Week Range

Investment Objective

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS  US Listed Pharmaceutical 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

No recent news for VanEck Pharmaceutical ETF.


1 month+8.65% 3 years+9.90%
3 months+11.47% 5 years+8.20%
1 year+10.92% Since inception+9.52%
Data through 12/03/2022

Quote Details

Previous close$77.88
Open day’s range77.29 – 78.08
Net asset value (NAV)78.11 (12/02/2022)
Daily volume5,282
Average volume (3 months)159,405
Data as of 4:00pm ET, 12/02/2022

Peer Comparisonvs. Health ETFs

Performance 5-yr return+8.20%+5.91%
Expense Gross exp ratio0.35%1.00%
Risk 5 year sharpe ratio0.450.45
Net assets$563.9M$2.0B
Average market cap$88.9B$49.7B
Average P/E18.023.2
Dividend / Share--0.27%


FHLC Fidelity MSCI Health Care Index ETF
VHT Vanguard Health Care Index Fund ETF Shar...
XLV Health Care Select Sector SPDR® Fund


Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
JNJ Johnson & Johnson9.10%
LLY Eli Lilly and Co6.05%
MRK Merck5.65%
ABBV AbbVie5.55%
BMY Bristol-Myers Squibb5.47%
PFE Pfizer5.26%
NVO Novo Nordisk5.04%
NVS Novartis4.86%
AZN AstraZeneca4.77%
SNY Sanofi4.66%